secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2026-08-06T11:10:16+00:00
Accession:  0001193125-26-336716
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q2 net income $22.7M; RGX-202 BLA on track; cash runway to Q4 2027
----------------------------------------------------------------------------

- Net income of $22.7M ($0.43 per share) vs net loss of $70.9M in Q2 2025; revenue $108.0M (incl. $100M AbbVie milestone).
- RGX-202 Phase III AFFINITY DUCHENNE trial met primary endpoint (p<0.0001); BLA submission on track for Q3 2026 with potential accelerated approval 2H 2027.
- RGX-121 BLA resubmission on track for Q3 2026 after positive FDA Type A meeting; no additional studies required.
- Sura-vec (ABBV-RGX-314) pivotal wet AMD data expected Q4 2026; first patient dosed in NAAVIGATE DR study triggered $100M milestone.
- Pro forma cash ~$313M after July 2026 milestone and public offering; cash runway extended into Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/0001193125-26-336716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer